US · CNMD · MEDICAL - DEVICES
CONMED Corporation (CNMD) intrinsic value and stock valuation
$46.56as of 2026-11-21 · Mkt cap 1.48B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
CONMED Corporation DCF and intrinsic value
InvestorsCraft values CNMD with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from CNMD’s statements →
CONMED Corporation Graham Number
Graham Number: $33.70d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B |
| Operating income | $141.1M | $200.3M | $120.6M | $70.1M | $109.7M |
| Net income | $47.1M | $132.4M | $64.5M | -$-80.58M | $62.5M |
| EPSd | $1.51M | $4.26M | $2.04M | -$-2.68M | $1.94M |
| Operating cash flow | $170.7M | $167M | $125.4M | $33.4M | $111.8M |
| Capital expenditure | -$-19.81M | -$-13.08M | -$-19.03M | -$-21.79M | -$-14.87M |
| Free cash flow | $150.9M | $153.9M | $106.3M | $11.6M | $96.9M |
| Total assets | $2.33B | $2.31B | $2.3B | $2.3B | $1.77B |
| Total debt | $834.9M | $905.8M | $991.3M | $1.05B | $684.7M |
| Net debt | $794.1M | $881.3M | $967M | $1.03B | $663.8M |
| Total equity | $1.03B | $962.7M | $834.2M | $745.5M | $785.4M |
| Cash and short-term investments | $40.8M | $24.5M | $24.3M | $28.9M | $20.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B |
| Cost of revenue | $649.1M | $574M | $568.5M | $474.2M | $442.6M |
| Gross profit | $725.4M | $733M | $676.3M | $571.3M | $568M |
| Research and development expenses | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M |
| Selling, general and administrative expenses | $528.4M | $478.3M | $503M | $454M | $414.8M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $584.2M | $532.7M | $555.6M | $501.2M | $458.3M |
| Cost and expenses | $1.23B | $1.11B | $1.12B | $975.4M | $900.9M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M |
| Depreciation and amortization | $52.3M | $71.9M | $71.9M | $49.8M | $70.7M |
| Ebitda | $154.6M | $272.2M | $192.5M | $7.8M | $179.3M |
| Operating income | $141.1M | $200.3M | $120.6M | $70.1M | $109.7M |
| Total other income/expenses, net | -$-70.01M | -$-37.3M | -$-39.77M | -$-140.92M | -$-36.61M |
| Income before tax | $71.1M | $163M | $80.8M | -$-70.86M | $73.1M |
| Income tax expense | $24.1M | $30.6M | $16.4M | $9.72M | $10.6M |
| Net income | $47.1M | $132.4M | $64.5M | -$-80.58M | $62.5M |
| Weighted average shares outstanding | $31M | $30.9M | $30.7M | $30M | $29.2M |
| Weighted average diluted shares outstanding | $31.2M | $31.1M | $31.6M | $30M | $32.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $40.8M | $24.5M | $24.3M | $28.9M | $20.9M |
| Net receivables | $247.8M | $237.7M | $242.3M | $191.3M | $183.9M |
| Inventory | $355.5M | $346.7M | $318.3M | $332.3M | $231.6M |
| Total current assets | $672.9M | $640M | $615.7M | $581.2M | $460.1M |
| Property, plant and equipment, net | $113.3M | $115.8M | $120.7M | $115.6M | $108.9M |
| Goodwill and intangible assets | $1.39B | $1.42B | $1.46B | $1.5B | $1.09B |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.65B | $1.67B | $1.68B | $1.72B | $1.31B |
| Total assets | $2.33B | $2.31B | $2.3B | $2.3B | $1.77B |
| Accounts payable | $93.7M | $102.3M | $88.2M | $73.4M | $58.2M |
| Short-term debt | $710K | $710K | $8.22M | $69.8M | $12.3M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $315M | $278.1M | $310.7M | $296.6M | $196.7M |
| Long-term debt | $834.2M | $905.1M | $983M | $985.1M | $672.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $977.6M | $1.07B | $1.16B | $1.26B | $783.9M |
| Capital lease obligations | $0.00 | $0.00 | $11.6M | $0.00 | $0.00 |
| Total liabilities | $1.29B | $1.34B | $1.47B | $1.55B | $980.6M |
| Common stock | $310K | $310K | $310K | $310K | $310K |
| Retained earnings | $588.8M | $560.3M | $452.5M | $412.6M | $496.6M |
| Accumulated other comprehensive income (loss) | -$-46.3M | -$-58.86M | -$-50.17M | -$-57.86M | -$-54.2M |
| Total equity | $1.03B | $962.7M | $834.2M | $745.5M | $785.4M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $834.9M | $905.8M | $991.3M | $1.05B | $684.7M |
| Net debt | $794.1M | $881.3M | $967M | $1.03B | $663.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $47.1M | $132.4M | $64.5M | -$-80.58M | $62.5M |
| Depreciation and amortization | $74.3M | $51.3M | $51.4M | $69.5M | $70.7M |
| Stock-based compensation | $28.3M | $25.6M | $24.3M | $21.7M | $16.3M |
| Change in working capital | -$-11.45M | -$-39.72M | -$-39.58M | -$-90.7M | -$-55.7M |
| Accounts receivable | -$-2.36M | -$-1.62M | -$-47.07M | -$-5.2M | -$-9.16M |
| Inventory | -$-6.73M | -$-31.63M | $14.1M | -$-78.56M | -$-37.81M |
| Accounts payable | -$-9.75M | $14.7M | $14.9M | $13.3M | $4.89M |
| Net cash provided by operating activities | $170.7M | $167M | $125.4M | $33.4M | $111.8M |
| Investments in property, plant and equipment | -$-19.81M | -$-13.08M | -$-19.03M | -$-21.79M | -$-14.87M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-227.74M | $0.00 |
| Net cash used for investing activities | -$-20.96M | -$-13.08M | -$-20.03M | -$-249.53M | -$-14.87M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $72M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | -$-72M | $0.00 |
| Dividends paid | -$-24.75M | -$-24.65M | -$-24.5M | -$-23.96M | -$-23.26M |
| Net cash used for financing activities | -$-135.82M | -$-151M | -$-110.43M | $225M | -$-101.55M |
| Net change in cash | $16.4M | $160K | -$-4.65M | $8.1M | -$-6.51M |
| Cash at end of period | $40.8M | $24.5M | $24.3M | $28.9M | $20.9M |
| Operating cash flow | $170.7M | $167M | $125.4M | $33.4M | $111.8M |
| Capital expenditure | -$-19.81M | -$-13.08M | -$-19.03M | -$-21.79M | -$-14.87M |
| Free cash flow | $150.9M | $153.9M | $106.3M | $11.6M | $96.9M |
Line items
Line items
Line items
About CONMED Corporation
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
- CEO
- Patrick J. Beyer
- Employees
- 3.9K
- Beta
- 0.93
Included in
Explore
Frequently asked questions
What is the intrinsic value of CONMED Corporation (CNMD)?
CONMED Corporation (CNMD) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CNMD undervalued?
CNMD trades at a price of $46.56 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.